Table I.

Multivariate analysis for the change in haemoglobin concentration in sickle cell anaemia patients treated with erythropoiesis-stimulating agents and/or hydroxycarbamide for one year at the University of Illinois at Chicago.

Variable	β	95% Confidence Interval	P Value
ESA therapy	0.64	0.05 – 1.22	0.035
New HC therapy	0.74	0.16 – 1.32	0.014
Stable HC therapy	0.95	0.37 – 1.54	0.002
Age	0.02	0.003 – 0.04	0.023
Advanced CKD	−0.27	−0.76 – 0.23	0.3

CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; HC, hydroxycarbamide, Advanced CKD defined as estimated glomerular filtration rate < 60 ml/min/1.73m²